![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Dsuvia, Sufenta, Zalviso |
Other names | R30730 |
AHFS/Drugs.com | Monograph |
License data |
|
Routes of administration | Intravenous therapy (IV), intramuscular injection (IM), subcutaneous injection (SQ), epidural, intrathecal, sublingual |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 53% (sublingual) |
Elimination half-life | 162 minutes |
Duration of action | 30 to 60 min[3] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.168.858 |
Chemical and physical data | |
Formula | C22H30N2O2S |
Molar mass | 386.55 g·mol−1 |
3D model (JSmol) | |
Melting point | 97 °C (207 °F) |
| |
| |
(verify) |
Sufentanil, sold under the brand names Dsuvia and Sufenta, is a synthetic opioid analgesic drug approximately 5 to 10 times as potent as its parent drug, fentanyl, and 500 to 1,000 times as potent as morphine. Structurally, sufentanil differs from fentanyl through the addition of a methoxymethyl group on the piperidine ring (which increases potency but is believed to reduce duration of action[4]), and the replacement of the phenyl ring by thiophene. Sufentanil first was synthesized at Janssen Pharmaceutica in 1974.[5]
Sufentanil is marketed for use by specialist centers[clarification needed] under different trade names, such as Sufenta and Sufentil. Sufentanil with and without lidocaine or mepivacaine is available as a transdermal patch similar to Duragesic in Europe under trade names such as Chronogesic. It is available as a sublingual tablet under the trade name Dsuvia.[6]
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search